Integral BioSystems
Integral BioSystems is a Bedford, Massachusetts-based pharmaceutical contract research organization founded in 2009, providing specialty formulation development and cGLP services across ophthalmic, injectable, and other delivery routes, while licensing proprietary OcuHeal™ LNP and NanoM Wafer™ drug delivery platforms to bio-pharmaceutical clients.
- Company typePrivate
- Founded2009
- HeadquartersBedford, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Integral BioSystems does
Integral BioSystems, LLC is a privately held contract research organization (CRO) founded in 2009 and fully operational since 2011, headquartered in Bedford, Massachusetts. The company provides specialty drug formulation development services for bio-pharmaceutical clients across multiple delivery routes including ophthalmic, injectable, dermal, otic, pulmonary, intranasal, oral, sublingual, and rectal dosage forms. Service offerings include formulation development, analytical method development, cGLP toxicology supply generation, and scale-up/technology transfer, executed from a ~10,000 sq ft cGLP-compliant laboratory facility.
The company's technology portfolio centers on proprietary drug delivery platforms designed to overcome bioavailability and sustained-release challenges. These include the OcuHeal™ Lipid Nanoparticle (LNP) platform using liquid-crystalline nanolipid structures with membrane-interactive permeation enhancers; the NanoM Wafer™ Ocular Insert technology with dissolvable and non-dissolvable thin-film variants; the OcuSurf™ Nanocore Delivery System for biphasic nano-dispersions; and the EySite Platform for PLGA microspheres with sub-0.5% burst release. These platforms are patented across 12-14 global jurisdictions and positioned for 505(b)(2) product development pathways.
Integral BioSystems operates a dual business model combining fee-for-service CRO engagements with out-licensing of proprietary delivery platforms. Revenue is generated through project-based CRO contracts (quote-based pricing by scope, molecule, and stage) and technology licensing collaborations. The company is owned by founders Dr. Shikha Barman (CEO/CTO) and Dave Karasic (COO/Legal/IP). In July 2022, the company established Symphony Therapeutics as a wholly-owned subsidiary to advance platform product commercialization, including OcuHeal-UV400+ (UV/blue-light protective eyedrop) and the NanoM-Wafer™ Artificial Tear Film Ocular Insert (dry-eye treatment), with Europe targeted as the initial proprietary-product market.
Integral BioSystems firmographics
Firmographics- Name
- Integral BioSystems
- Legal name
- Integral BioSystems, LLC
- Website
- https://integralbiosystems.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Integral BioSystems is a Bedford, Massachusetts-based pharmaceutical contract research organization founded in 2009, providing specialty formulation development and cGLP services across ophthalmic, injectable, and other delivery routes, while licensing proprietary OcuHeal™ LNP and NanoM Wafer™ drug delivery platforms to bio-pharmaceutical clients.
- Ownership category
- akta.pro rank
Integral BioSystems industry classification
Industry- Product category
- Pharmaceutical Contract Research & Drug Delivery Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in Nanotechnology (541713)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Process Development & Tech Transfer (Upstream/Downstream/MSAT) (HLAGAGAE)
- akta.pro secondary industry
- Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where Integral BioSystems is headquartered
LocationHeadquarters
- HQ city
- Bedford
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Integral BioSystems business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- CRO Fee-for-Service Contracts: Contract research organization services including formulation development, analytical method development, cGLP toxicology supply generation, and scale-up/technology transfer. Services billed on project basis with pricing quote-based.
- Technology Licensing: Out-licensing of proprietary delivery platforms (OcuHeal™ LNP and NanoM Wafer™) to pharmaceutical companies for 505(b)(2) product development. Company seeks licensing collaborations for additional applications in ophthalmology, urology, and intranasal routes.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Integral BioSystems product offering
Product offeringCore offering
Integral BioSystems is a contract research organization that provides drug delivery and formulation development services for ocular, dermatologic, and nano-medicine applications. The company develops and licenses proprietary drug delivery platforms including OcuHeal™ LNP, NanoM Wafer™, OcuSurf™, and EySite for sustained, targeted, and nanoparticle-based delivery of small molecules and biologics. Through its subsidiary Symphony Therapeutics, it advances clinical-stage ophthalmic assets for pharmaceutical partners.
Product overview
Integral BioSystems operates as a pharmaceutical contract research organization (CRO) offering a hybrid model of fee-for-service CRO work and proprietary, licensable drug delivery platforms. The core product portfolio includes two main platform technologies: the OcuHeal™ LNP (Lipid Nanoparticle) Platform and the NanoM Wafer™ Sustained-Release Ocular Insert Platform, both of which are patented globally and available for licensing. The OcuSurf™ Nanocore Delivery System represents an earlier iteration of the lipid nanoparticle technology for ophthalmic formulations. The EySite Platform provides PLGA microsphere-based sustained delivery for the posterior segment. Under the wholly-owned subsidiary Symphony Therapeutics (founded July 2022), the company advances product-specific applications including OcuHeal-UV400+ (UV-protective eyedrop) and the NanoM-Wafer™ Artificial Tear Film Ocular Insert for dry eye treatment. CRO services span formulation development, analytical method development, and scale-up across multiple delivery routes including ophthalmic, injectable, dermal, and pulmonary applications.
Differentiator
Problem solved
Functional benefit
Brands
- OcuHeal: Lipid nanoparticle (LNP) platform technology for ocular, otic, intranasal, and dermal drug delivery applications. The platform is patented globally and used for 505(b)(2) products.
- NanoM Wafer
- OcuSurf
- EySite
Products and services
- OcuHeal™ LNP Proprietary lipid nanoparticle-based ocular drug delivery platform for sustained and targeted delivery of small molecules and biologics to the eye. Targeted at bio-pharmaceutical partners developing ophthalmic therapeutics.
- NanoM Wafer™ Proprietary nano-medicine wafer-based delivery platform for sustained release drug delivery applications. Targeted at pharmaceutical developers requiring controlled-release formulations.
- OcuSurf™ Proprietary ocular drug delivery platform for topical/surface-based ophthalmic delivery of therapeutics. Targeted at bio-pharmaceutical partners developing eye drop and surface-acting ophthalmic products.
- EySite Proprietary ophthalmic drug delivery platform supporting site-specific ocular therapeutics delivery. Targeted at bio-pharmaceutical developers of targeted ophthalmic drugs.
- Drug Delivery Formulation CRO Services Contract research services encompassing formulation development, analytical method development, and characterization for ocular, dermatologic, and nano-medicine drug delivery programs. Targeted at bio-pharmaceutical R&D teams.
- Symphony Therapeutics (Subsidiary) Clinical Development Clinical-stage ophthalmic development arm operating as a subsidiary, advancing ophthalmic therapeutic assets derived from Integral BioSystems' delivery platforms. Targeted at pharmaceutical partners seeking clinical-translational ophthalmic development.
Quantifiable outcome
- Free base formulation delivered ~80% more total drug recovered from corneal tissue compared to hydrochloride salt (88.8 μg vs 49.0 μg)
- +2 more outcomes
Companies that use Integral BioSystems
Customer profileNamed customers17 records
Segments3 records
Ideal customer profiles1 record
Integral BioSystems technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Integral BioSystems partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Symphony TherapeuticscoreWholly-owned subsidiary founded July 2022, used to advance platform products including OcuHeal™ and NanoM Wafer™. Symphony Therapeutics conducts investor outreach and identifies development partners for delivery platforms. Initial market introduction targeted for Europe.
- Nacuity PharmaceuticalscoreCollaboration and license deal for NanoM™ technology. Nacuity Pharmaceuticals licensed Integral BioSystems' NanoM™ drug formulation technology for development of ophthalmic products.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
Integral BioSystems competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key highlights7 records
Customer concentration
Integral BioSystems social profiles
Digital presenceIntegral BioSystems financial estimates
Financial estimateRevenue estimate
Valuation estimate
Integral BioSystems leadership team
Management profileNumber of profiles
Profiles2 records
Integral BioSystems subsidiaries and ownership
Company hierarchySubsidiaries1 record
Integral BioSystems funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Integral BioSystems M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Integral BioSystems
What does Integral BioSystems do?
Integral BioSystems is a contract research organization that provides drug delivery and formulation development services for ocular, dermatologic, and nano-medicine applications. The company develops and licenses proprietary drug delivery platforms including OcuHeal™ LNP, NanoM Wafer™, OcuSurf™, and EySite for sustained, targeted, and nanoparticle-based delivery of small molecules and biologics. Through its subsidiary Symphony Therapeutics, it advances clinical-stage ophthalmic assets for pharmaceutical partners.
Is Integral BioSystems a public or private company?
Integral BioSystems is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Integral BioSystems founded?
Integral BioSystems was founded in 2009. It employs 11 to 50 people.
Where is Integral BioSystems based?
Integral BioSystems is headquartered in Bedford, United States, in the North America region.
How does Integral BioSystems make money?
Two revenue lines are on record. CRO Fee-for-Service Contracts are the primary driver. The others are technology Licensing.
Does Integral BioSystems have an API?
No public API is recorded for Integral BioSystems.
What industry is Integral BioSystems in?
Integral BioSystems's product category is Pharmaceutical Contract Research & Drug Delivery Services. Its primary akta.pro industry code is HLAGAGAE, Process Development & Tech Transfer (Upstream/Downstream/MSAT), with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 541714 and its SIC code is 8731.